# Halozyme Therapeutics market performance

> Live situation record from CLSTR: https://clstr.news/situations/halozyme-therapeutics-market-performance
> Updated: 2026-08-24T11:46:49.000Z. Sources: 4. Developments: 2.

Halozyme Therapeutics reached a new 52-week high, with share prices hitting $109.10 and a market capitalization of $12.33 billion. 

Financial analysts have responded with mixed but generally positive ratings. Leerink Partners upgraded the stock from ‘market perform’ to ‘outperform’ with a $110.00 target, and Wall Street Zen issued a ‘strong-buy’ rating. While institutions like UBS Group and Benchmark maintained ‘buy’ ratings, Morgan Stanley adjusted its price objective to $93.00. The consensus among nine analysts is a ‘Buy’ rating, despite three ‘Hold’ ratings and one ‘Sell’ rating, with an average target price of $91.20.

## Timeline

### 2026-08-24: Halozyme Therapeutics shares reach new 52-week high

Halozyme Therapeutics (HALO) reached a new 52-week high of $109.10, supported by several analyst upgrades and a market capitalization of $12.33 billion.

2 sources. https://clstr.news/cluster/halozyme-therapeutics-shares-reach-new-52-week-high

### 2026-08-19: Haleon and Halozyme report corporate financial activities

Haleon plc announced results for a $1.34 billion tender offer of its 2027 senior notes, while Halozyme Therapeutics CEO Helen Torley sold 20,000 shares via a pre-arranged trading plan.

3 sources. https://clstr.news/cluster/haleon-and-halozyme-report-corporate-financial-activities

---
Cite as: Halozyme Therapeutics market performance. CLSTR, https://clstr.news/situations/halozyme-therapeutics-market-performance